Indian Journal of Drugs in Dermatology

REVIEW ARTICLE
Year
: 2020  |  Volume : 6  |  Issue : 1  |  Page : 5--12

Rituximab in dermatology: Revisited


Aditya Kumar Bubna 
 Department of Dermatology, IQ City Medical College, Sovapur, Jemua, Durgapur, West Bengal, India

Correspondence Address:
Dr. Aditya Kumar Bubna
Department of Dermatology, IQ City Medical College, Sovapur, Bijra Road, Jemua, Durgapur - 713 206, West Bengal
India

Rituximab (RTX) is a specific mouse and human chimeric monoclonal antibody that has found to have numerous applications in dermatology. Though initially approved by the US FDA for treating rheumatoid arthritis and non-Hodgkin's lymphoma; currently its approval has extended to involve the pemphigus group of disorders; both as a first line drug as well as a therapeutic strategy for recalcitrant cases of pemphigus, unresponsive to conventional therapy. Apart from pemphigus, there have been a number of cutaneous disorders where rituximab has been found to be useful. This review will give a bird's eye view of the applications of rituximab in dermatology.


How to cite this article:
Bubna AK. Rituximab in dermatology: Revisited.Indian J Drugs Dermatol 2020;6:5-12


How to cite this URL:
Bubna AK. Rituximab in dermatology: Revisited. Indian J Drugs Dermatol [serial online] 2020 [cited 2020 Aug 7 ];6:5-12
Available from: http://www.ijdd.in/article.asp?issn=2455-3972;year=2020;volume=6;issue=1;spage=5;epage=12;aulast=Bubna;type=0